Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study

Journal of the American Academy of Dermatology

Volumn 70, Issue 3, 2014, Pages 517-524

  Van Der Voort, Ella A M ^a   Koehler, Edith M ^a   Dowlatshahi, Emmilia A ^a   Hofman, Albert ^a   Stricker, Bruno H ^a   Janssen, Harry L A ^a   Schouten, Jeoffrey N L ^a   Nijsten, Tamar ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

comorbidity; liver disease; metabolic syndrome; nonalcoholic fatty liver disease; psoriasis

Indexed keywords

COMORBIDITY; LIVER DISEASE; METABOLIC SYNDROME; NONALCOHOLIC FATTY LIVER DISEASE; PSORIASIS;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COMORBIDITY; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GERIATRIC ASSESSMENT; HUMANS; LIFE STYLE; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PREVALENCE; PROGNOSIS; PSORIASIS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 84894091047     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.10.044     Document Type: Article

References (41)

1. M. Hamaguchi, T. Kojima, N. Takeda, T. Nakagawa, H. Taniguchi, and K. Fujii et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease Ann Intern Med 143 2005 722 728
2. G. Musso, R. Gambino, M. Cassader, and G. Pagano Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 43 2011 617 649
3. G.N. Ioannou, E.J. Boyko, and S.P. Lee The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002 Am J Gastroenterol 101 2006 76 82 (Pubitemid 43381712)
4. K.S. Wenk, K.C. Arrington, and A. Ehrlich Psoriasis and non-alcoholic fatty liver disease J Eur Acad Dermatol Venereol 25 2011 383 391
5. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
6. S. Bellentani, G. Saccoccio, F. Masutti, L.S. Croce, G. Brandi, and F. Sasso et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy Ann Intern Med 132 2000 112 117 (Pubitemid 30044177)
7. L.A. Adams, P. Angulo, and K.D. Lindor Nonalcoholic fatty liver disease CMAJ 172 2005 899 905 (Pubitemid 40543601)
8. W.J. Taylor, E. Korendowych, P. Nash, P.S. Helliwell, E. Choy, and G.G. Krueger et al. Drug use and toxicity in psoriatic disease: focus on methotrexate J Rheumatol 35 2008 1454 1457 (Pubitemid 352000803)
9. P. Gisondi, G. Targher, G. Zoppini, and G. Girolomoni Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis J Hepatol 51 2009 758 764
10. S. Madanagobalane, and S. Anandan The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India Australas J Dermatol 53 2012 190 197
11. L. Miele, S. Vallone, C. Cefalo, G. La Torre, C. Di Stasi, and F.M. Vecchio et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis J Hepatol 51 2009 778 786
12. W.H. Boehncke Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting J Rheumatol 39 2012 441 444
13. B.B. Davidovici, N. Sattar, J.C. Prinz, L. Puig, P. Emery, and J.N. Barker et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions J Invest Dermatol 130 2010 1785 1796
14. A.B. Kimball, A. Guerin, D. Latremouille-Viau, A.P. Yu, S. Gupta, and Y. Bao et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis Am J Med 123 2010 350 357
15. A. Hofman, C.M. van Duijn, O.H. Franco, M.A. Ikram, H.L. Janssen, and C.C. Klaver et al. The Rotterdam study: 2012 objectives and design update Eur J Epidemiol 26 2011 657 686
16. E.A. Dowlatshahi, M. Kavousi, T. Nijsten, M.A. Ikram, A. Hofman, and O.H. Franco et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study J Invest Dermatol 133 2013 2347 2354
17. R.G. Langley, and C.N. Ellis Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment J Am Acad Dermatol 51 2004 563 569 (Pubitemid 39278075)
18. M. Hamaguchi, T. Kojima, Y. Itoh, Y. Harano, K. Fujii, and T. Nakajima et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation Am J Gastroenterol 102 2007 2708 2715 (Pubitemid 350179336)
19. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, and B.A. Franklin et al. Diagnosis and management of the metabolic syndrome-an American Heart Association/National Heart, Lung, and Blood Institute scientific statement Circulation 112 2005 2735 2752 (Pubitemid 41532612)
20. T.M. Wallace, J.C. Levy, and D.R. Matthews Use and abuse of HOMA modeling Diabetes Care 27 2004 1487 1495 (Pubitemid 38680001)
21. E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gotzsche, and J.P. Vandenbroucke et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies BMJ 335 2007 806 808 (Pubitemid 350057266)
22. G. Marchesini, R. Marzocchi, F. Agostini, and E. Bugianesi Nonalcoholic fatty liver disease and the metabolic syndrome Curr Opin Lipidol 16 2005 421 427 (Pubitemid 41017626)
23. A. Kotronen, and H. Yki-Jarvinen Fatty liver: a novel component of the metabolic syndrome Arterioscler Thromb Vasc Biol 28 2008 27 38
24. E.M. Koehler, J.N. Schouten, B.E. Hansen, F.J. van Rooij, A. Hofman, and B.H. Stricker et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study J Hepatol 57 2012 1305 1311
25. P. Loria, A. Lonardo, S. Bellentani, C.P. Day, G. Marchesini, and N. Carulli Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question Nutr Metab Cardiovasc Dis 17 2007 684 698 (Pubitemid 47593074)
26. G. Targher, F. Marra, and G. Marchesini Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51 2008 1947 1953
27. K.T. Uysal, S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 1997 610 614 (Pubitemid 27446179)
28. E.A. Dowlatshahi, E.A. van der Voort, L.R. Arends, and T. Nijsten Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis Br J Dermatol 169 2013 266 282
29. T. Nijsten, and M. Wakkee Complexity of the association between psoriasis and comorbidities J Invest Dermatol 129 2009 1601 1603
30. Y.Y. Li Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease World J Gastroenterol 18 2012 6546 6551
31. G.K. Perera, P. Di Meglio, and F.O. Nestle Psoriasis Annu Rev Pathol 7 2012 385 422
32. G. Langman, P.M. Hall, and G. Todd Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury J Gastroenterol Hepatol 16 2001 1395 1401 (Pubitemid 34107409)
33. P. Rosenberg, H. Urwitz, A. Johannesson, A.M. Ros, J. Lindholm, and N. Kinnman et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment J Hepatol 46 2007 1111 1118 (Pubitemid 46669734)
34. R. Rivera, and F. Vanaclocha Nonalcoholic fatty liver disease and psoriasis [in Spanish] Actas Dermosifiliogr 101 2010 657 658
35. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, and K. Cusi et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609
36. R.S. Stern, T. Nijsten, S.R. Feldman, D.J. Margolis, and T. Rolstad Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction J Investig Dermatol Symp Proc 9 2004 136 139 (Pubitemid 38457271)
37. D. Amarapurkar, P. Kamani, N. Patel, P. Gupte, P. Kumar, and S. Agal et al. Prevalence of non-alcoholic fatty liver disease: population-based study Ann Hepatol 6 2007 161 163 (Pubitemid 350277193)
38. C.H. Chen, M.H. Huang, J.C. Yang, C.K. Nien, C.C. Yang, and Y.H. Yeh et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan J Gastroenterol Hepatol 22 2007 1482 1489
39. J. Frith, C.P. Day, E. Henderson, A.D. Burt, and J.L. Newton Non-alcoholic fatty liver disease in older people Gerontology 55 2009 607 613
40. H. Li, Y.J. Wang, K. Tan, L. Zeng, L. Liu, and F.J. Liu et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China Hepatobiliary Pancreat Dis Int 8 2009 377 382
41. S.H. Park, W.K. Jeon, S.H. Kim, H.J. Kim, D.I. Park, and Y.K. Cho et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults J Gastroenterol Hepatol 21 2006 138 143